Navigation Links
CryoLife Reports Financial Results for the Third Quarter and First Nine Months of 2011
Date:10/27/2011

iness development opportunities arise. In the normal course of its business, CryoLife explores potential strategic transactions and, depending on the timing of any future transactions, business development costs could be higher or lower than currently anticipated, which could materially affect operating expenses and earnings.  CryoLife has also inherited certain risks and uncertainties related to its recent acquisition of Cardiogenesis' business. These risks and uncertainties include that CryoLife's ability to maintain revenues and achieve growth in revenues from Cardiogenesis' revascularization technology in the future is dependent upon physician awareness of this technology as a safe, efficacious, and appropriate treatment for their patients; CryoLife may not be able to successfully market Cardiogenesis' revascularization technology if third-party reimbursement for the procedures performed with this technology is not available for its health care provider customers, or if suppliers or manufacturers with respect to Cardiogenesis products fail to comply with ongoing FDA or other foreign regulatory authority requirements, CryoLife's Cardiogenesis business may be negatively impacted; third-party distributors or CryoLife's own distributors may not effectively distribute Cardiogenesis products; CryoLife's international operations with respect to Cardiogenesis subject it to certain operating risks, which could adversely impact its net sales, results of operations, and financial condition; Cardiogenesis has been named as a defendant in a patent infringement lawsuit and costly litigation may be necessary to protect or defend its intellectual property rights; and Cardiogenesis' internal controls over financial reporting may not have been effective prior to the merger, which could have a significant and adverse effect on CryoLife.  These risks and uncertainties related to Cardiogenesis' business that CryoLife has inherited also include the risk factor
'/>"/>

SOURCE CryoLife, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. CryoLife Announces First Implant of Combination Aortic-Mitral Allograft Heart Valve at the Cleveland Clinic
2. CryoLife Receives FDA Approval to Begin U.S. Clinical Trial for BioFoam(R)
3. CryoLife Reports Record Quarterly Revenues of $28.2 Million
4. CryoLife to Present at Upcoming Investor Conferences in New York
5. CryoLife to Present at 21st Annual Piper Jaffray Health Care Conference
6. CryoLife Provides Initial 2010 Financial Guidance
7. CryoLife Enters into Worldwide Distribution and Manufacturing Agreements with Starch Medical for Novel Hemostatic Agent
8. CryoLife Receives Japanese Regulatory Approval for BioGlue Surgical Adhesive
9. CryoLife Announces Release Date and Teleconference Call Details for 2010 Third Quarter Financial Results
10. CryoLife Begins Distribution of Blood-Clotting Agent PerClot® in Europe
11. CryoLife to Present at Lazard Capital Markets 7th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 27, 2015  Valeant Pharmaceuticals International, Inc. (NYSE: ... its previously announced registered offering of common shares in ... Pursuant to the Offering, the Company issued 7,286,432 common ... aggregate gross proceeds of approximately $1.45 billion. On March ... and Exchange Commission a final prospectus supplement to its ...
(Date:3/27/2015)...   Hospira, Inc. (NYSE: HSP ... world,s leading provider of injectable drugs and infusion ... of biosimilarity of its proposed biosimilar, Epoetin Hospira, ... conditionally approved name of RETACRIT™, compared to the ... data were presented at the National Kidney Foundation ...
(Date:3/27/2015)... March 27, 2015  Delcath Systems, Inc. (NASDAQ: ... device company focused on oncology with an emphasis ... cancers, announces the reporting of data from a ... for Injection with the Delcath Hepatic Delivery System ... at the Society of Surgical Oncology (SSO) Annual ...
Breaking Medicine Technology:Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 3Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5
... Jan. 28, 2011 Drug safety remains front and ... the agency strives to improve the public,s perception of ... improving its reputation among consumers and recognizes that its ... important role in that effort. One issue ...
... Burg Simpson Eldredge Hersh & Jardine, P.C., one of the ... that shareholder, Seth. A. Katz, has been appointed by the ... the Plaintiffs, Steering Committee in the multidistrict litigation against DePuy Orthopaedics, ... Hip System. In August 2010, DePuy Orthopaedics, Inc., ...
Cached Medicine Technology:Navigating the Gray Areas of Post-Marketing Surveillance 2Burg Simpson Leads National Litigation Against DePuy Orthopaedics, Inc. 2
(Date:3/28/2015)... AZ (PRWEB) March 28, 2015 Coffee could ... also help protect you from gum disease, researchers have found. ... against gum disease. , Coffee contains antioxidants. Antioxidants fight gum ... the question researchers at Boston Univ. Henry M. Goldman School ... in the August 2014 issue of the Journal of Periodontology. ...
(Date:3/28/2015)... 2015 With more than 4,500 ... of osteoporosis, osteoarthritis and musculoskeletal diseases gathered here ... be the first time in the 17-year history ... the hot-button topic is an emerging non-pharmaceutical protocol ... scientific principles of Wolff’s law, osteogenic loading at ...
(Date:3/28/2015)... March 28, 2015 India Network ... is made available to all visitors who purchase the ... All members are encouraged to purchase the insurance program ... lack of proper coverage for pre-existing medical conditions. Parents ... or two medical conditions with serious consequences to their ...
(Date:3/28/2015)... 2015 One in three young athletes ... presented today at the American Orthopaedic Society for Sports ... the long term success of surgery for patients aged ... data from 242 patients who underwent ACL reconstruction between ... MBBS, FRACS, from North Sydney Orthopaedic and Sports Medicine ...
(Date:3/28/2015)... Genomic medicine experts have sequenced the ... the first time, key information for understanding and treating ... newly posted story on the Surviving Mesothelioma website. ... Columbia, the British Columbia Cancer Agency, and PhenoPath lab ... molecular alterations and mutations that can lead to ...
Breaking Medicine News(10 mins):Health News:New Research Impliments Coffee May Help Fight Gum Disease and Increasing Benefits With Tylers Coffee 2Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2Health News:New Genomics Research May Help Doctors Tailor Mesothelioma Treatment, According to Surviving Mesothelioma 2
... to use fertility treatment to create a "saviour sibling" for ... has issued a licence to a clinic allowing it to ... will be a donor for a very ill baby. ... called diamond blackfan anaemia and her only hope of survival ...
... Stephanie Mullen, a type 1 diabetic has been reported missing ... run out of medication// leaving her gravely ill, police have ... left her home in Uphall, at 2 pm on Monday. ... female friend in Livingston. She is white, 5 ft 2in, ...
... by the defence attorneys of the AIIMS hospital, has sought ... where a boy, suffering from cancer, got inflicted with AIDS ... ,The victim, who was nine years old at the ... for treatment of cancer, supposedly has contracted HIV due to ...
... analyze the risk attitudes and consequences of college drinking ... takers compared to women// who are inclined to use ... drinking in the company of friends, counting the number ... of money spent on drinking. ,Steve Benton, ...
... have tolled up 100,000 hours of time as they collaborated ... bird flu.// Researchers eleven UK universities and research labs have ... could be effective against the H5N1 virus. ,The ... help particle physicists examine the huge amounts of data from ...
... of the child is not being revealed in Grampian. NHS there ... time it took up.// Expectant mothers are not being told about ... not because we are getting it wrong but because of time ... get the sex right. When you aggregate that over a day ...
Cached Medicine News:Health News:A Boy Undergoing Treatment For Cancer Gets AIDS At AIIMS 2Health News:Risk Attitudes And Consequences Of College Drinking 2Health News:UK Computer Grid In Bird Flu Fight 2Health News:UK Computer Grid In Bird Flu Fight 3
... Roche Diagnostics Task Targeted Automation ... state-of-the-art automation of pre- and ... decapping, sorting / archiving of ... bar code labeled secondary tubes. ...
... The Roche Diagnostics Task ... a state-of-the-art automation of ... the laboratories: decapping, sorting / ... aliquoting into bar code labeled ...
... Save precious time and gain efficiency ... Lab Automation System (LAS), the high-throughput ... sample-processing capabilities. The Olympus OLA2500 LAS ... designed for medium- to high-volume laboratories. ...
The Freedom EVO series platform offers a choice of flexible, scalable solutions for current and future application needs....
Medicine Products: